Drug Profile
Research programme: biosimilars - mAbxience
Alternative Names: Adnx01; Adnx02; Adnx03; Adnx04; mAbx03; mAbx04; mAbx05; mAbx06; mAbx07; mAbx08; mAbx09Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator mAbxience
- Class Colony-stimulating factors; Hormones; Interferons; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antigen modulators; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in Switzerland (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Switzerland (Parenteral)
- 31 Jul 2013 Research programme: biosimilars - mAbxience is available for licensing as of 31 Jul 2013. http://www.mabxience.com